Rheumatic Disease
Virtual Grand Rounds
Treatment Options for the Patient
With Refractory RA
 |
||
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: September 14, 2011
Expiration Date: September 14, 2012
Estimated Time of Completion: 30 minutes
Description
The purpose of this activity is to discuss management strategies for patients with refractory RA.
Objectives
- Review potential causes of TNF inhibitor nonresponse or discontinuation.
- Discuss available data on switching to another TNF inhibitor or biologic with a different mechanism of action after inadequate response to an initial TNF inhibitor.
- Interpret the safety and efficacy data of sequential therapy with one or more biologic DMARDs.
Target Audience
This activity is intended for rheumatologists, primary care physicians, and other clinicians who treat patients with rheumatic diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), gout, systemic lupus erythematosus (SLE), and antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV).
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director
Leonard H. Calabrese, DO
Professor of Medicine
RJ Fasenmyer Chair of Clinical Immunology
Vice Chairman, Department of Rheumatic and Immunologic Diseases
Cleveland Clinic Lerner College of Medicine
Cleveland, Ohio
Faculty
Marc Cohen, MD
Emeritus Professor of Medicine
Mayo Clinic
Rochester, Minnesota
Adjunct Clinical Professor of Medicine
National Jewish Health
Denver, Colorado
Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated that he may have a relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:
Leonard Calabrese, DO |
||
| Amgen Inc.: |
Consulting, Teaching and Speaking | |
| Bristol-Myers Squibb Company: | Consulting, Teaching and Speaking | |
| Centocor, Inc.: | Consulting, Teaching and Speaking | |
| Pfizer Inc.: | Consulting, Teaching and Speaking | |
| Roche-Genentech: | Consulting, Teaching and Speaking | |
The following faculty has indicated that he has no relationships which, in the context of her presentation, could be perceived as potential conflicts of interest:
Marc Cohen, MD
The Cleveland Clinic Foundation Center for Continuing Education acknowledges
educational grants for partial support of this activity from:
Abbott Laboratories
Genentech, Inc.
This CME activity was produced by the
Cleveland Clinic Foundation Center for Continuing Education and
